Answers are grounded in this paper and cite their sources.
Case report reveals fatal immune-mediated toxicity in DLBCL, suggesting late-onset CAR-T challenges.
Chimeric antigen receptor (CAR) T-cell therapy has dramatically improved the prognosis of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [1,2]. However, immune-mediated toxicities represent a significant emerging clinical challenge, particularly those with late onset or uncommon presentations. We report the case of a 71-year-old woman with heavily pretreated DLBCL who developed immune effector cell–associated hemophagocytic syndrome (IEC-HS) with a fatal outcome six months following CAR-T infusion. This case highlights the occurrence of late -onset CAR-T-related toxicities and the potential role of CAR-T cell persistence in sustaining dysregulated immune activation.
No takes yet. Share an insight, caveat, or question.
Rincón-López et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: